Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients

doi:10.1186/1479-5876-7-1

Journal of Translational Medicine

Volume 7

Viewing options:

Abstract
Full text
PDF (616KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Kobayashi J
Torigoe T
Hirohashi Y
Idenoue S
Miyazaki A
Yamaguchi A
Hiratsuka H
Sato N

on PubMed

Kobayashi J
Torigoe T
Hirohashi Y
Idenoue S
Miyazaki A
Yamaguchi A
Hiratsuka H
Sato N
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research

Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients

Jun-ichi Kobayashi¹^,2 , Toshihiko Torigoe¹ , Yoshihiko Hirohashi¹ , Satomi Idenoue³ , Akihiro Miyazaki² , Akira Yamaguchi² , Hiroyoshi Hiratsuka² and Noriyuki Sato¹

¹Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

²Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

³Department of Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

author email corresponding author email

Journal of Translational Medicine 2009, 7:1doi:10.1186/1479-5876-7-1


Published:	6 January 2009

Abstract

Background

We previously reported an HLA-A24-restricted cytotoxic T-cell epitope, Survivin-2B80-88, derived from a splice variant of survivin, survivin-2B. In this report, we show a novel HLA-A24-restricted T-cell epitope, Survivin-C58, derived from a wild type survivin, and compared their immunogenicity in oral cancer patients.

Methods

By stimulating peripheral blood lymphocytes of HLA-A24-positive cancer patients with Survivin-C58 peptide in vitro, the peptide-specific CTLs were induced. In order to compare the immunogenic potential between C58 peptide and 2B80-88 peptide, peripheral blood T-cells from thirteen HLA-A24-positive oral cancer patients were stimulated with either or both of these two peptides.

Results

Survivin-2B80-88 peptide-specific CTLs were induced from four patients, and C58 peptide-specific CTLs were induced from three out of eight patients with over stage II progression. The CTLs exerted cytotoxicity against HLA-A24-positive tumor cells. In contrast, CTL induction failed from a healthy volunteer and all four patients with cancer stage I.

Conclusion

It was indicated that a splicing variant-derived peptide and wild type survivin-derived peptide might have a comparable potency of CTL induction, and survivin targeting immunotherapy using survivin-2B80-88 and C58 peptide cocktail should be suitable for HLA-A24+ oral cancer patients.